CN106924548A - 一种缓解疲劳的药物及制备方法 - Google Patents
一种缓解疲劳的药物及制备方法 Download PDFInfo
- Publication number
- CN106924548A CN106924548A CN201710280800.7A CN201710280800A CN106924548A CN 106924548 A CN106924548 A CN 106924548A CN 201710280800 A CN201710280800 A CN 201710280800A CN 106924548 A CN106924548 A CN 106924548A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- chinese medicine
- black fungus
- aqueous extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 129
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 241000233866 Fungi Species 0.000 claims abstract description 82
- 239000006286 aqueous extract Substances 0.000 claims abstract description 39
- 239000000463 material Substances 0.000 claims abstract description 31
- 241000894007 species Species 0.000 claims abstract description 27
- 239000007788 liquid Substances 0.000 claims abstract description 26
- 240000005373 Panax quinquefolius Species 0.000 claims abstract description 20
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 20
- 229940079593 drug Drugs 0.000 claims abstract description 18
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims abstract description 15
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 14
- 244000241872 Lycium chinense Species 0.000 claims abstract description 14
- 240000000759 Lepidium meyenii Species 0.000 claims abstract description 13
- 235000000421 Lepidium meyenii Nutrition 0.000 claims abstract description 13
- 235000012902 lepidium meyenii Nutrition 0.000 claims abstract description 13
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 12
- 240000004638 Dendrobium nobile Species 0.000 claims abstract description 10
- 239000001963 growth medium Substances 0.000 claims abstract description 9
- 238000012360 testing method Methods 0.000 claims description 39
- 238000000855 fermentation Methods 0.000 claims description 36
- 230000004151 fermentation Effects 0.000 claims description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 230000001580 bacterial effect Effects 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 13
- 241000196324 Embryophyta Species 0.000 claims description 12
- 241000282994 Cervidae Species 0.000 claims description 11
- 235000015097 nutrients Nutrition 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 9
- 230000002779 inactivation Effects 0.000 claims description 8
- 239000002609 medium Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 239000002699 waste material Substances 0.000 claims description 7
- 229930006000 Sucrose Natural products 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 229940041514 candida albicans extract Drugs 0.000 claims description 5
- 239000002054 inoculum Substances 0.000 claims description 5
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 5
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 5
- 239000006916 nutrient agar Substances 0.000 claims description 5
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 5
- 239000012138 yeast extract Substances 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 4
- 229960001763 zinc sulfate Drugs 0.000 claims description 4
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 4
- 238000003809 water extraction Methods 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000012549 training Methods 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 41
- 230000036039 immunity Effects 0.000 abstract description 22
- 235000013305 food Nutrition 0.000 abstract description 8
- 230000036541 health Effects 0.000 abstract description 7
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 230000001662 opsonic effect Effects 0.000 abstract description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 49
- 239000002775 capsule Substances 0.000 description 41
- 206010016256 fatigue Diseases 0.000 description 35
- 210000004369 blood Anatomy 0.000 description 22
- 239000008280 blood Substances 0.000 description 22
- 150000004676 glycans Chemical class 0.000 description 21
- 229920001282 polysaccharide Polymers 0.000 description 21
- 239000005017 polysaccharide Substances 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 16
- 241000221377 Auricularia Species 0.000 description 15
- 230000006870 function Effects 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 12
- 239000012153 distilled water Substances 0.000 description 12
- 230000037396 body weight Effects 0.000 description 11
- 238000003304 gavage Methods 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 10
- 230000007812 deficiency Effects 0.000 description 9
- 239000003651 drinking water Substances 0.000 description 9
- 235000020188 drinking water Nutrition 0.000 description 9
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 8
- 244000241838 Lycium barbarum Species 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 235000015459 Lycium barbarum Nutrition 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000002929 anti-fatigue Effects 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 102100026189 Beta-galactosidase Human genes 0.000 description 5
- 229920002527 Glycogen Polymers 0.000 description 5
- 108010059881 Lactase Proteins 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000003712 anti-aging effect Effects 0.000 description 5
- 108010005774 beta-Galactosidase Proteins 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 229940096919 glycogen Drugs 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 229940116108 lactase Drugs 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000003305 oral gavage Methods 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000001835 viscera Anatomy 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000009182 swimming Effects 0.000 description 4
- 230000001256 tonic effect Effects 0.000 description 4
- 206010002660 Anoxia Diseases 0.000 description 3
- 241000976983 Anoxia Species 0.000 description 3
- 241000723353 Chrysanthemum Species 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 241001506047 Tremella Species 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000007953 anoxia Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- -1 flavone compound Chemical class 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000009629 microbiological culture Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001106041 Lycium Species 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000000767 anti-ulcer Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 244000285940 beete Species 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 2
- 229940116229 borneol Drugs 0.000 description 2
- 150000001720 carbohydrates Chemical group 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 235000011222 chang cao shi Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000012286 potassium permanganate Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000219193 Brassicaceae Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282985 Cervus Species 0.000 description 1
- 241000283007 Cervus nippon Species 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 241000331528 Chlorophytum capense Species 0.000 description 1
- 235000009604 Chrysanthemum X morifolium Nutrition 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 235000002710 Ilex cornuta Nutrition 0.000 description 1
- 241001310146 Ilex cornuta Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- CMUNUTVVOOHQPW-LURJTMIESA-N L-proline betaine Chemical compound C[N+]1(C)CCC[C@H]1C([O-])=O CMUNUTVVOOHQPW-LURJTMIESA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- PEFASEPMJYRQBW-HKWQTAEVSA-N Robinin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O1 PEFASEPMJYRQBW-HKWQTAEVSA-N 0.000 description 1
- 244000181025 Rosa gallica Species 0.000 description 1
- 235000000533 Rosa gallica Nutrition 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000005686 Serum Globulins Human genes 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 235000015177 dried meat Nutrition 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 230000009567 fermentative growth Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- YUCFVHQCAFKDQG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH] YUCFVHQCAFKDQG-UHFFFAOYSA-N 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000007674 genetic toxicity Effects 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- DDELFAUOHDSZJL-UHFFFAOYSA-N kaempferol 3-O-rutinoside-7-O-rhamnoside Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC1=C(C=2C=CC(O)=CC=2)OC2=CC(OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C1=O DDELFAUOHDSZJL-UHFFFAOYSA-N 0.000 description 1
- PEFASEPMJYRQBW-UHFFFAOYSA-N kaempferol 7-O-alpha-L-rhamnopyradoside 3-O-beta-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(OC4C(C(O)C(O)C(C)O4)O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O1 PEFASEPMJYRQBW-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000079 pharmacotherapeutic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000010341 ping gan Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920001197 polyacetylene Polymers 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- PEFASEPMJYRQBW-XMWKPCQISA-N robinin Natural products O(C[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](OC2=C(c3ccc(O)cc3)Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@@H](O)[C@@H](C)O4)c3)C2=O)O1)[C@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 PEFASEPMJYRQBW-XMWKPCQISA-N 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- CMUNUTVVOOHQPW-ZCFIWIBFSA-N stachydrine Natural products C[N+]1(C)CCC[C@@H]1C([O-])=O CMUNUTVVOOHQPW-ZCFIWIBFSA-N 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明“一种缓解疲劳的药物及制备方法”,属于中药组合物,是黑木耳母种以中药原料药混合物的中药水提取液为培养基的发酵产物;所述中药原料药混合物的重量份组份为:玛咖15~45份、枸杞子10~35份、西洋参5~15份、石斛25~35份、银耳15~35份、菊花10~30份。所述药物的制备方法是将黑木耳母种液接种到所述水提取液中发酵。本发明药物为中成药,对压力过大的人群具有整体调理作用,并能改善亚健康状况,提高免疫力并缓解疲劳的疗效。本发明药物为保健药,没有任何的毒副作用,可以当食品服用。
Description
技术领域
本发明涉及功能保健食品,具体地说明是涉及一种缓解疲劳的药物及其制备方法。
背景技术
现代社会的竞争加剧,节奏加快,现代人长期处于紧张的生活环境,工作压力大及过度疲劳,加上不正常的生活饮食习惯,造成过度疲劳并导致内分泌、神经系统、消化系统失调,进而病变。
疲劳虽是人体正常的生理反应,但长期积蓄会造成过度疲劳,发展成为病理状态。疲劳是人们熟悉但又十分复杂的一种现象,不论从事何种事业,随着劳动时间延长,均会出现疲劳,表现为作业能力下降,感觉疲倦,对任何用力都感到厌倦等。造成疲劳的原因有很多,随着科学技术的发展,生活中的污染产生了各种有害物质,如药物、食品添加剂等释放的过氧化物;手机、电视、电脑等产生的辐射等,这些因素破坏人体细胞的完整性、稳定性、工作压力加大,劳动组织和制度不合理,长时间就会造成机体疲劳。长期疲劳会导致过早衰老,疲劳不仅损害机体健康,导致疾病,而且能使机体早衰,缩短人的正常寿命。因此如何减缓疲劳,增强免疫力,已成为全社会都关注的问题。
发明内容
根据上述领域的需求和不足,本发明提供一种缓解疲劳的药物及其制备方法。本发明药物为中成药,对压力过大的人群具有整体调理作用,并能改善亚健康状况起到提高免疫力以及缓解疲劳的疗效。本发明药物为保健药,没有任何的毒副作用,可以当食品服用。
本发明提供一种缓解疲劳的药物,其特征在于,是黑木耳母种以中药原料药混合物的中药水提取液为培养基的发酵产物;所述中药原料药混合物的重量份组份为:玛咖15~45份、枸杞子10~35份、西洋参5~15份、石斛25~35份、银耳15~35份、菊花10~30份。
所述中药原料药混合物的重量份组份为:玛咖25、枸杞子20份、西洋参10份、石斛30份、银耳25份、菊花20份。
所述黑木耳母种指黑木耳试管母种,接种量为每100kg所述中药水提取液中接种5~15管18mm×180mm规格的所述试管母种。
所述黑木耳母种指黑木耳菌丝母种液,接种量为:黑木耳菌丝母种液与中药水提取液的体积比例为5~15:100。
所述黑木耳菌丝母种液是由黑木耳试管母种以含有辅料的中药水提取液作为液体培养基制备而得,所述辅料的重量份组份为:磷酸氢二钾8份、磷酸二氢钾7份、硫酸锌2份、鹿胎粉10份、白糖40份、酵母浸膏20份、营养琼脂培养基100份,所述辅料占液体培养基的6~10%(w/w)。
以上述的药物为有效成分的药剂。
上述的缓解疲劳的药物的制备方法,其特征在于:将黑木耳母种接种到所述中药水提取液中发酵。
所述发酵的步骤为:
(1)制备中药水提取液:向所述中药原料药的混合物中加饮用水煎煮提取4~5次,每次过滤取药汁,最后一次弃渣,合并所取的药汁得中药水提取液,所述中药水提取液的总质量是原料药总重量的5~10倍;
(2)接种:对所述中药水提取液进行常压灭活,待冷却至常温,接种黑木耳菌丝母种;
(3)深层发酵:发酵时间为72~144小时。
所述常压灭活指常压下水蒸汽灭活12小时,所述深层发酵72~144小时后,还需对发酵产物进行放罐、浓缩、焙干、过筛最后得粉状制品。
技术效果:
本发明提供一种缓解疲劳的药物,是黑木耳母种以中药原料药混合物的水提取液为液体培养基进行共菌发酵的产物,本发明主要是通过提取中药原料药的水提取液,然后在中药水提取液中接种黑木耳菌丝母种液,进行深层发酵。本发明的制备方法中的优选的的方案中,试管黑木耳母种扩繁成菌丝液时所用的液体培养基为本发明配伍好的中药水提取液,这样能够使黑木耳菌丝预先适应以中药水提取液为培养基的扩繁环境,并使中药中的各种植物多糖与黑木耳多糖在发酵和深层发酵中发生两次缀合过程,形成复杂的大分子杂多糖,使本发明的药物中含有更高含量,更多种类的多糖缀合物,使其在缓解疲劳,增强机体免疫力方面的效果更显著。服用本制品后,患者的免疫系统将受到植物多糖,木耳多糖,氨基酸以及它们的缀合物大分子物质的主动刺激,这使得本发明的制品在缓解疲劳,增强机体免疫力的功效更显著,整体上既治标又固本。
在一些实施例中,黑木耳母种指液体菌丝母钟,液体菌丝母种是在深层发酵之前,用部分水提取液作为液体培养基,并在液体培养基中加入磷酸氢二钾、磷酸二氢钾、硫酸锌、鹿胎粉、白糖、酵母浸膏、营养琼脂培养基等辅料制成母种的液体培养基,接种黑木耳试管母种后发酵而得。在这样些实施例中,中药中的植物多糖、鹿胎粉中的动物多糖以及木耳多糖发生发酵缀合过程,使得本发明的产品中大分子杂多糖的种类和比例都大幅度增加,从而在缓解疲劳以及提高免疫力方面效果更显著。
到目前为止没有报道过黑木耳菌种在缓解疲劳病症方面的作用,本发明将黑木耳保护、修复脏腑脾肺、益气以及活血养血方面的效果,结合西洋参的滋阴益气、润肺降火、清热除烦、提高体力和脑力劳动的能力,降低疲劳度和调节中枢神经系统;枸杞子的增强机体免疫功能,抗疲劳;玛咖的抗疲劳、抗氧化、提高免疫力、延缓衰老;银耳的益气清肠、安眠健胃、补脑、养阴清热、润燥,石斛的益胃生津,滋阴清热及菊花的疏散风热等方面的功效,以及其他中药原料药的功效,共同发酵,各有效成分在发酵过程中相互间产生了协同作用,增强作用效果,并且各有效成分的效果相互得到增强;该药物通过养血活血,顺通脉络,修复脏腑,补气培元,祛虚扶损清火,宁心安神达到增强免疫力,缓解疲劳,全面调节机体状态的效果,并且无任何毒副作用。
黑木耳:富含黑木耳多糖,黑木耳母种在发酵生长过程中产生多种酶,能够充分将原料药的水提取液中的糖元转化为合成木耳多糖的原料,变废为宝,通过发酵过程提高木耳多糖含量,节约成本。本发明的药物中,木耳多糖具有修复组织损伤、抗溃疡形成、提高机体免疫力并缓解疲劳的功能,对于本发明的药物发挥保护、修复脏腑脾肺,补气养血,疏通脉络具有重要的作用,其它几味原料药所起的作用各有偏重,共同相辅相成给予免疫力低下,过度疲劳以及长期疲劳的患者调和补的作用,而原料药成分经过提取和发酵,其药效成分更纯,毒副作用更小。本发明的实验例证明本发明提供的药物提高患者免疫力,缓解疲劳方面,“标”和“本”兼治,使机体恢复到正常健康的代谢周期,疗程结束后不产生对药物的依赖。具体每种药物成分的作用简介如下:
黑木耳菌丝,菌丝体无色透明,是由许多横隔膜和分枝的管状菌丝组成,它是黑木耳分解和吸取养分的营养器官。性味归经:甘,平。功能主治:补气血,润肺,止血。用于气虚血亏,四肢搐搦,肺虚咳嗽,咯血,吐血,衄血,崩漏,高血压病,便秘。黑木耳菌丝在生长发育过程中,能分泌多种酶,对木质有很强的分解能力。木耳菌丝发酵过程中能将原料药中的木质素,纤维素、半纤维素分解成自身所需的C源,并合成木耳多糖,木耳多糖具有以下保健功能:1.降血糖。木耳多糖对四氧嘧啶糖尿病小鼠高血糖有防治作用,使实验小鼠葡萄糖耐受量及耐受量曲线得到明显改善,还能减少糖尿病小鼠饮水量。(《中国药科大学学报》1989,3;《浙江食用菌》1993,1),2.降血脂:木耳多糖能明显降低高血脂症大鼠血清游离胆固醇、胆固醇脂、三酰甘油、β-脂蛋白含量,降低高胆固醇引起的小鼠高胆固醇血症的形成。(《中国药科大学学报》1989,6;《第五届全国药用真菌学术会议论文集》1990)。3.抑制血小板凝聚,4.抗血栓形成:木耳多糖可明显延长家兔特异性血栓及纤维蛋白血栓的形成时间,缩短血栓长度,减轻血栓湿重和干重,减少血小板数,降低血小板粘附率和血液粘度,并可明显缩短豚鼠优球蛋白溶解时间,降低血浆纤维蛋白原含量,升高纤溶酶活性,具有明显抗血栓形成的作用。(《药用真菌》1988,1)。5.提高机体免疫功能:木耳多糖对机体免疫功能有明显促进作用,包括增加脾指数,半倍溶血值和E玫瑰花结形成率,促进巨噬细胞吞噬功能和淋巴细胞转化率,增强机体细胞免疫和体液免疫功能,具有显著的抗肿瘤活性。(《南京药学院学报》1985,3;《中国药科大学学报》1989,4)。6.抗衰老:木耳多糖可使小鼠心肌组织褐脂质含量下降,使脑和肝中超氧化物歧化酶活力增加,对小鼠离体脑B型单氨氧化酶(MAO-B)活性起抑制作用,提示木耳多糖具有抗衰老活性。(《中国药科大学学报》1989,5)。7.对组织损伤具有修复作用:木耳多糖有明显增强核酸和蛋白质代谢的作用,能增加肝微粒体含量,促进血清蛋白质的生物合成,增强机体抗病能力,对机体损伤有保护作用。(《中国药科大学学报》1989,5;《南京药学院学报》1985,3)。8.改善心肌缺氧:木耳多糖能延长小鼠常压耐缺氧实验的生存时间,提高生存率,提示木耳多糖有对改善缺血心肌对氧的供求失调有一定作用。(《第五届全国药用真菌学术会议论文集》1990)。9.抗溃疡形成:木耳多糖能明显抑制大鼠应激型溃疡的形成,促进醋酸型胃溃疡的愈合,表明木耳多糖对抗胃溃疡形成的作用。(《广西中医药》1982,2)。本发明中所用的黑木耳菌丝母种,对菌种菌株没有特殊要求,市场上可买到的优质黑木耳菌丝母种即可。
西洋参提取物是西洋参提取加工后的提取物。西洋参为五加科植物西洋参Panaxquinque folium L.的干燥根,性凉、味甘、微苦,入心、肺、肾经,具有滋阴益气、润肺降火、清热除烦、生津止渴的功能,能够提高体力和脑力劳动的能力,降低疲劳度和调节中枢神经系统等药理作用;对高血压、心肌营养性不良、冠心病、心绞痛等心脏病均有较好的疗效,西洋参中主要含有人参皂苷类成分,以及有机酸、聚乙炔类、甾族化合物,糖类、挥发油、无机元素等几大类。西洋参是药食同源植物,系名贵中药,含有人体必需的16种微量元素、17种以上氨基酸和多糖、多肽及多种维生素等,具有抗癌、抗疲劳、抗缺氧、抗辐射、抗衰老等多种功能,为高级滋补佳品。临床对冠心病、高血压、贫血、神经官能症、糖尿病等治疗具有很好疗效。西洋参性寒,四季均可进补,年老或病后体虚者、身体素质较差者、脑力劳动者、内分泌不调者,以及不适合用人参进补的年轻人,都可服用。现代临床中药学研究表明,西洋参可用于以下几种情况:(1)肺肾阴虚火旺所致的咳嗽痰少或痰中带血等症;(2)外感热病或内伤病久导致气阴两伤所见的烦倦口渴等症;(3)内热消渴,津液亏虚所致口干舌燥等症;(4)肠热津亏所致便血症;(5)癌症患者因放射治疗或化学治疗所致的不良反应;(6)高血压、冠心病、心绞痛等患者,尤其是心脏病引起的烦躁、闷热、口渴等症状突出者;(7)调节中枢神经平衡及具有一定程度的抗疲劳、抗缺氧等作用。
菊花(拉丁学名:Dendranthema morifolium(Ramat.)Tzvel.):在植物分类学中是菊科、菊属的多年生宿根草本植物。菊花的主要成分有挥发油(0.20-/0-0.85%)、腺嘌呤、胆碱、水苏碱、菊苷及黄酮类化合物。挥发油主要有龙脑、樟脑、菊酮和醋酸龙脑酷等成分,黄酮类成分有木樨草素、芹菜素、刺槐素等。此外,菊花中还含有丰富的维生素、氨基酸、微量元素等。菊花味微辛、甘、苦,性微寒。能疏散风热,清肝明目,平肝阳,解毒。用于感冒风热,发热头昏;肝经有热;目赤多泪,或肝肾阴虚,眼目昏花;肝阳上亢,眩晕头痛;疮疡肿痛。现代又用于冠心病、高血压病。
枸杞为人们对商品枸杞子、植物宁夏枸杞、中华枸杞等枸杞属下物种的统称。枸杞子滋补肝肾,益精明目。《本草纲目》记载:枸杞,补肾生精,养肝……明目安神,令人长寿。近代药理实验表明:枸杞子具有增强机体免疫功能,抑制肿瘤,降血糖,降血脂,抗疲劳等功能作用。枸杞(Lycium chinense Miller)是茄科枸杞属的一种植物,为常用中药,功能主治为:治肝肾阴亏,益精明目。用于虚劳精亏,腰膝酸痛,眩晕耳鸣,阳痿遗精,内热消渴,血虚萎黄,目昏不明。现代研究表明:枸杞具有提高免疫力的活性、降血糖活性、抗脂肪肝活性。
玛咖(Lepidium meyenii Walpers)是十字花科独行菜属的一种植物,原产于秘鲁安第斯山区,当地人主要用其作为食物,也作为传统药物使用,目前在云南省大量引种。玛咖是卫生部新批准的新资源食品,具有很高的营养素价值,有抗疲劳、抗氧化、提高免疫力、延缓衰老、改善性功能、减少前列腺增生、提高生育能力等多种功能。研究表明它能延长小鼠负重游泳时间,增加小鼠的肝糖原的储备量,还可以降低运动前后血乳酸变化值。
石斛(Herba Dendrobii),补益药类;别名:林兰、禁生、杜兰、金钗花、千年润、黄草、吊兰花;性味归经:微寒;甘;归胃、肾经;功能主治:益胃生津,滋阴清热。用于阴伤津亏,口干烦渴,食少干呕,病后虚热,目暗不明。
银耳又称作白木耳、雪耳、银耳子、白耳子、白耳、桑鹅、五鼎芝等,属于真菌类银耳科银耳属,是门担子菌门真菌银耳的子实体,有"菌中之冠"的美称。银耳所含化学成分较为复杂,初步分析证明,银耳含蛋白质6.7%-10%、碳水化合物65%-71.2%、脂肪0.6%-12.8%、粗纤维2.4%-2.75%、无机盐4.0%-5.4%、水分15.2%-18.76%及少量维生素B类。银耳的蛋白质中含有亮氨酸、异亮氨酸、苯丙氨酸、氨酸、丝氨酸、谷氨酸、撷氨酸、脯氨酸、精氨酸、赖氨酸、丙氨酸、苏氨酸、天门冬氨酸、酪氨酸、胱氨酸、组氨酸、甲硫氨酸等17种氨基酸,其中含量最大的是脯氨酸。无机盐中主要含硫、铁、镁、钙、钾等离子。银耳中还含有海藻糖、多缩戊糖、甘露糖醇等肝糖,营养价值很高,具有扶正强壮的作用,是一种高级滋养补品,银耳中还有较丰富的膳食纤维。银耳味甘、淡、性平、无毒,既有补脾开胃的功效,又有益气清肠、滋阴润肺的作用。既能增强人体免疫力,又可增强肿瘤患者对放、化疗的耐受力。银耳富有天然植物性胶质,外加其具有滋阴的作用,是可以长期服用的良好润肤食品。银耳具有强精、补肾、润肠、益胃、补气、和血、强心、壮身、补脑、提神、美容、嫩肤、延年益寿之功效。它能提高肝脏解毒能力,保护肝脏功能,它不但能增强机体抗肿瘤的免疫能力,还能增强肿瘤患者对放疗、化疗的耐受力。可以滋补生津;润肺养胃,补肺益气。虚劳咳嗽;痰中带血;津少口渴;病后体虚;气短乏力。银耳也是一味滋补良药,特点是滋润而不腻滞,具有补脾开胃、益气清肠、安眠健胃、补脑、养阴清热、润燥之功,对阴虚火旺不受参茸等温热滋补的病人是一种良好的补品。银耳富有天然特性胶质,加上它的滋阴作用,长期服用可以润肤,并有祛除脸部黄褐斑、雀斑的功效。
鹿胎粉是用梅花鹿或马鹿的胎制成。鹿胎粉粉质细腻,颜色深黄,气味酥香。现代科学证明:鹿胎中含有17种氨基酸、22种无机成分、多种维生素及酮、雌酮硫酸盐、雌二醇和6种特定脂溶性成分,据《本草纲目》记载:“鹿胎调经养颜解诸毒”,具有补精血、返少阳的作用,是女性滋补调养、延缓衰老的极品。鹿胎粉为药食同源的产品,服用期间没有禁忌,可以正常服用。
本发明还提供上述药物的制备方法,主要是先将配伍好的原料药西洋参,菊花,枸杞子,玛咖,石斛,银耳进行煎煮提取药用成分,去药渣后在提取液中接种适量的黑木耳母种,然后在适宜温度下深层发酵72~144小时,能够保证发酵充分,有效固体物含量高,多糖含量高,其获得的药物治疗功效最好,依照深层发酵时,罐内外的温度和培养基的养分及通氧量的不同,而发酵时间可以有所不同。
本发明生产过程简单,非常适合企业规模化生产,并且毒副作用小,作用持久,经济实惠。
具体实施方式
提供下述实施例是为了更好地进一步理解本发明,并不局限于所述最佳实施方式,不对本发明的内容和保护范围构成限制,任何人在本发明的启示下或是将本发明与其他现有技术的特征进行组合而得出的任何与本发明相同或相近似的产品,均落在本发明的保护范围之内。
实施例中未注明具体实验步骤或条件者,按照本领域内的文献所描述的常规实验步骤的操作或条件即可进行。所用试剂或仪器未注明生产厂商者,均为可以通过市购获得的常规试剂产品。
本发明中只选取实施例4制备的胶囊来做增强免疫力和缓解疲劳方面的实验,并不代表其他实施例所制备的胶不具有本发明所述的效果;需要说明的是本发明发明人在申请日之前也同样做过实施例1,2,3所制备的胶囊的增强免疫力和缓解疲劳方面功能性实验,其中实施例1,2,3所制备的胶囊也能达到与实施例4制备的胶囊相似的效果。
实施例1.药物制备
步骤1.中药水提取液制备
中药原料及其重量份:玛咖25、枸杞子20份、西洋参10份、石斛30份、银耳25份、菊花20份;
1)按上述原料药组分一共称取28kg,置于150kg饮用水中,大火煮沸,并用小火再煎煮三小时,过滤取汁约得到30~55kg,留药渣;
2)再注入130kg饮用水,大火煮沸后小火再煎煮约三小时,过滤取汁约得到30~50kg,留药渣;
3)重复步骤2)4~5次,最后一次弃渣;
4)将上述几步的药汁合并,得总计重量约150kg中药水提取液。
步骤2.制备黑木耳菌丝母种液
材料:黑木耳母种ACCC 50438:中国农业微生物菌种保藏管理中心(AgriculturalCulture Collection of China英文缩写ACCC),保藏编号50438;
上述黑木耳母种,申请人实验室亦有保存,并制备成试管黑木耳菌丝母种液,自申请日起二十年可向公众发放用于实验研究。用于本发明的黑木耳母种也可以是商购途径得到,没有特别要求。
材料:
1.步骤1的中药水提取液
2.营养琼脂培养基;(上海中药昆虫生物科技开发有限公司康乐培养基厂)
3.酵母浸膏;(北京双旋微生物培养基制品厂)
4.磷酸氢二钾;(广东汕头西陇化工厂)
5.硫酸锌(分析纯);(上海兴塔化工厂)
6.鹿胎粉;(双阳区文举鹿产品经销处)
7.磷酸二氢钾;(青岛市广汇化工厂)
8.白糖;(超市购买)
9.高锰酸钾;(天津恒兴化学制剂有限公司)
10.福尔马林;(山东济南试剂厂)
11.菌丝母种试管。
器具:
1.500ml玻璃瓶;
2.手提高压锅,电煤双用;(上海申仪三厂)
3.摇床:D4-900;(江苏太仑市实验设备厂)
4.超净工作台;
5.酒精灯;
6.勾、耙、针、刀;
7.火柴;
8.消毒棉花;
9.75%乙醇;
10.橡皮筋。
方法:
1)在15kg步骤1得到的中药水提取液内分别加入
磷酸氢二钾80g、磷酸二氢钾70g、硫酸锌20g、鹿胎粉100g、白糖400g、酵母浸膏20g、,搅拌并加温至100℃,放入营养琼脂培养基1000g,溶化后再添加中药水提取液制成25kg混浊液。
2)将12.5kg混浊液注入500ml玻璃瓶内,每瓶400ml,一共得12瓶,置入手提高压锅内在0.012MP/cm2,30min,取出后冷却至28℃~34℃,放入超净工作台内。
3)工具和器具以及灭活后的培养基放入超净工作台内,用30g高锰酸钾置入盛有50%福尔马林30ml的器皿中,接种用的勾、耙、针、刀放入该器皿中灭菌30min。将试管内黑木耳菌丝母种,切成3份,每份分别接入400ml/瓶的混浊液内,静养120min~150min。
4)在摇床上以20次/min,振荡72~96小时即分别得到黑木耳菌丝母种液。
步骤3.深层发酵
将步骤1获得的中药水提取液置于题为《食用菌液体菌种培养罐的罐盖及培养罐》专利号为ZL03270560.3的发酵罐中作为发酵底物。并将发酵罐推入《饱和蒸气无压锅炉》专利号为ZL200320126611.8的的锅炉中常压水蒸汽灭活12小时。待罐内底物冷却至28~34℃时,用名称为“食用菌液体注射杆及包含该注射杆的注射器”专利号为ZL200320126960.X的接种注射器,将步骤2制备得到的黑木耳菌丝母种液注入到中药水提取液中;接种量:黑木耳菌丝母种液与中药水提取液的体积比例为10~15:100,在22~28℃(黑木耳菌丝生长适宜温度为:22~28℃)环境下深层发酵72~144小时,放罐。
步骤4.制取药物:
放罐后得到的深层发酵产物,进行浓缩,焙干,过筛得粉状制品8kg,部分保留粉剂状态,制成胶囊,每粒含0.35g粉剂。
实施例2
步骤1.中药水提取液制备
所述中药原料药混合物的重量份组份为:玛咖15份、枸杞子35份、西洋参5份、石斛27份、银耳31份、菊花10份;
1)按上述原料药组分一共称取20kg,置于120kg饮用水中,大火煮沸,并用小火再煎煮三小时,过滤取汁约得到35~55kg,留药渣;
2)再注入125kg饮用水,大火煮沸后小火再煎煮约三小时,过滤取汁约得到30~45kg,留药渣;
3)重复步骤2)3~5次,最后一次弃渣;
4)将上述几步的药汁合并,得总计重量约150kg中药水提取液。
其它步骤同实施例1.
实施例3
步骤1.中药水提取物制备
所述中药原料药混合物的重量份组份为:玛咖45份、枸杞子10份、西洋参15份、石斛23份、银耳20份、菊花25份;
1)按上述原料药组分一共称取30kg,置于150kg饮用水中,大火煮沸,并用小火再煎煮三小时,过滤取汁约得到40~55kg,留药渣;
2)再注入130kg饮用水,大火煮沸后小火再煎煮约三小时,过滤取汁约得到30~55kg,留药渣;
3)重复步骤2)2次,最后一次弃渣;
4)将上述几步的药汁合并,得总计重量约150kg中药水提取液。
其它步骤同实施例1.
实施例4
用于本实施例中的黑木耳母种为购买自中国农业科学院农业微生物菌种保藏中心的试管母种(试管规格18mm×180mm),保藏号:Accc 50134。
申请人实验室亦有保存,自申请日起二十年可向公众发放用于实验研究。
步骤1.中药水提取液制备
中药原料及其重量份:
所述中药原料药混合物的重量份组份为:玛咖35份、枸杞子30份、西洋参13份、石斛35份、银耳15份、菊花30份。
1)按上述原料药组分一共称取25kg,置于140kg饮用水中,大火煮沸,并用小火再煎煮三小时,过滤取汁约得到30~50kg,留药渣;
2)再注入130kg饮用水,大火煮沸后小火再煎煮约三小时,过滤取汁约得到30~55kg,留药渣;
3)重复步骤2)3次,最后一次弃渣;
4)将上述几步的药汁合并,得总计重量约150kg中药水提取液。
步骤2.用购买的保藏号为Accc 50134的黑木耳试管母种进行深层发酵
将步骤1获得的中药水提取液置于题为《食用菌液体菌种培养罐的罐盖及培养罐》专利号为ZL03270560.3的发酵罐中作为发酵底物。并将发酵罐推入《饱和蒸气无压锅炉》专利号为ZL200320126611.8的的锅炉中常压水蒸汽灭活12小时。待罐内底物冷却至28~34℃时,用名称为“食用菌液体注射杆及包含该注射杆的注射器”专利号为ZL200320126960.X的接种注射器,每100kg中药水提取液中接种5~15管(18mm×180mm)黑木耳试管母种,在18~30℃(黑木耳菌丝生长适宜温度为:15~36℃)环境下进行深层发酵,72~144小时后放罐。步骤3.制取药物:
放罐后得到的深层发酵产物,进行浓缩,焙干,过筛得粉状制品7.9kg,部分保留粉剂状态,制成胶囊,每粒含0.35g粉剂。
实验例.以下通过实验数据,说明本发明的效果。
毒理试验:
试验目的:检验产品是否具有毒性
试验材料:实施例4制得的胶囊
样品:人体口服推荐量为0.35g/粒,每日2次,每次3粒。成人体重按60kg计算,折合剂量0.035g/kg·bw(0.035克/千克·体重)。取胶囊内容物进行试验
实验动物:清洁级昆明种小鼠、SD大鼠及饲料
实验环境条件:温度22-24℃,湿度52-58℃。
试验方法:
通过小鼠急性毒性试验(取实施例4制得的胶囊25g,加蒸馏水至50mL,取此液一日内间隔4小时给小鼠经口灌胃,共计灌胃2次,每次灌胃体积为0.2mL/10g·bw,累计计量为20.0g/kg·bw);Ames试验(取实施例4制得的胶囊1.25g,加蒸馏水至25mL,为5000μg/皿的剂量(每皿0.1mL),试验设五个剂量,分别为5000μg/皿、1000μg/皿、200μg/皿、40μg/皿、8μg/皿,加入菌株培养,同时设自发回变、溶剂对照和阳性突变剂对照);小鼠骨髓嗜多染红细胞微核试验(以40mg/kg·bw剂量的环磷酰胺为阳性对照,蒸馏水为阴性对照,试验组3个剂量分别为10.0g/kg·bw、5.0g/kg·bw、2.5g/kg·bw,取实施例4制得的胶囊50.0g、25.0g、12.5g分别加蒸馏水至100mL,配成相应剂量的受试液,给小鼠经口灌胃,灌胃体积为0.2mL/10g·bw);小鼠精子畸形试验(以40mg/kg·bw剂量的环磷酰胺为阳性对照,蒸馏水为阴性对照,试验组3个剂量分别为10.0g/kg·bw、5.0g/kg·bw、2.5g/kg·bw,取实施例4制得的胶囊50.0g、25.0g、12.5g分别加蒸馏水至100mL,配成相应剂量的受试液,给小鼠经口灌胃,灌胃体积为0.2mL/10g·bw);30天喂养试验(取实施例4制得的胶囊8.75g/kg·bw、17.5g/kg·bw、35.0g/kg·bw加蒸馏水定容至100mL,试验组3个剂量分别为0.88g/kg·bw、1.75g/kg·bw、3.50g/kg·bw对照组给与等体积蒸馏水,每日给大鼠经口灌胃一次,连续30天)来进行毒理学实验评定。
试验结果:
1、急毒经口毒性试验结果:对雌性、雄性昆明种小鼠的最大耐受剂量(MTD)均大于20.0g/kg·bw,属无毒级;
2、三项遗传毒性试验结果Ames试验、小鼠骨髓嗜多染红细胞微核试验、小鼠精子畸形试验结果均为阴性;
3、30天喂养试验结果:以0.88g/kg·bw、1.75g/kg·bw、3.50g/kg·bw剂量(相当于人体推荐剂量的25、50、100倍)给大鼠灌胃30天,试验期间,动物生长发育良好,各剂量组体重、增重、食物利用率、血常规指标、血生化指标、脏器湿重及脏器/体重比值与对照组比较,无明显差异(P>0.05)。大体解剖和组织病理检查未见与样品有关的异常改变。
功能试验:
试验目的:检验产品是否具有该项增强免疫力、缓解体力疲劳的功能。
1、增强免疫力功能:
试验材料:
样品:实施例4制得的胶囊,人体口服推荐量为0.35g/粒,每日2次,每次3粒。
成人体重按60kg计算,折合剂量0.035g/kg·bw。取胶囊内容物进行试验
试验动物:清洁级昆明种雌性小鼠200只,体重为18-22g
试验环境条件:屏障系统。温度22-24℃,湿度52-58%
剂量选择及样品处理:设实施例4的胶囊低、中、高剂量分别为0.175g/kg·bw、0.35g/kg·bw、1.05g/kg·bw(分别相当于人体推荐剂量的5、10、30倍)。低、中、高剂量受试液配置时,分别取胶囊内容物1.75g、3.50g、10.50g加蒸馏水定容至200mL,对照组予以等体积的蒸馏水,分别给予受试动物灌胃,每天灌胃一次,灌胃体积为0.2mL/kg·bw,连续30天。
主要仪器及试剂:动物台秤、分析天平、洁净工作台、二氧化碳培养箱、高压灭菌器、滤器、离心机、722分光光度计、恒温水浴箱、酶标仪、显微镜等。
试验方法:通过脏器/体重比值测定、迟发型变态反应、ConA诱导的小鼠淋巴细胞转化实验、抗体生成细胞检测、半数溶血值的测定、小鼠碳廓清实验、小鼠腹腔巨噬细胞吞噬鸡红细胞实验、NK细胞活性的测定实验来进行功能评定。
试验结果:
经口给与小鼠0.175g/kg·bw、0.35g/kg·bw、1.05g/kg·bw剂量的实施例4的胶囊30天,0.35g/kg·bw、1.05g/kg·bw剂量能增强小鼠迟发型变态反应、提高小鼠的抗体生成细胞数、提高小鼠的NK细胞活性,1.05g/kg·bw剂量能提高小鼠单核-巨噬细胞碳廓清的能力、提高小鼠淋巴细胞转化能力、提高小鼠血清半数溶血值,P<0.05。对小鼠体重增长、脾脏/体重比值、胸腺/体重比值、巨噬细胞吞噬鸡红细胞的能力未见明显影响(P>0.05)。在本实验条件下,提示该样品具有增强免疫力的功能。
具体试验结果数据见下表:
表1实施例4的胶囊对小鼠迟发型变态反应(DTH)的影响
由表1可知,经口给予小鼠不同剂量的实施例4的胶囊30天,中、高剂量组足跖肿胀度明显高于对照组,差异有显著性(P<0.05)。
表2实施例4的胶囊对小鼠ConA诱导的小鼠淋巴细胞转化能力实验的影响
由表2可知,经口给予小鼠不同剂量的实施例4的胶囊30天,高剂量组小鼠淋巴细胞转化能力明显高于对照组,差异有显著性(P<0.05)。
表3实施例4的胶囊对小鼠抗体生成细胞数的影响
由表3可知,经口给予小鼠不同剂量的实施例4的胶囊30天,中、高剂量组抗体生成细胞数明显高于对照组,差异有显著性(P<0.05)。
表4实施例4的胶囊对小鼠半数溶血值(HC50)的影响
由表4可知,经口给予小鼠不同剂量的实施例4的胶囊30天,高剂量组小鼠半数溶血值明显高于对照组,差异有显著性(P<0.05)。
表5实施例4的胶囊对小鼠单核-巨噬细胞碳廓清的影响
由表5可知,经口给予小鼠不同剂量的实施例4的胶囊30天,高剂量组小鼠吞噬指数明显高于对照组,差异有显著性(P<0.05)。
表6实施例4的胶囊对小鼠NK细胞活性的影响
由表6可知,经口给予小鼠不同剂量的实施例4的胶囊30天,中、高剂量组小鼠NK细胞活性明显高于对照组,差异有显著性(P<0.05)。
2、缓解体力疲劳功能:
试验材料:
样品:实施例4制得的胶囊,人体口服推荐量为0.35g/粒,每日2次,每次3粒。
成人体重按60kg计算,折合剂量0.035g/kg·bw。取胶囊内容物进行试验
试验动物:清洁级昆明种雄性小鼠160只,体重为18-22g
试验环境条件:屏障系统。温度22-24℃,湿度52-58%
剂量选择及样品处理:设实施例4的胶囊低、中、高剂量分别为0.175g/kg·bw、0.35g/kg·bw、1.05g/kg·bw(分别相当于人体推荐剂量的5、10、30倍)。低、中、高剂量受试液配置时,分别取胶囊内容物1.75g、3.50g、10.50g加蒸馏水定容至200mL,对照组予以等体积的蒸馏水,分别给予受试动物灌胃,每天灌胃一次,灌胃体积为0.2mL/kg·bw,连续30天
主要仪器及试剂:动物台秤、分析天平、离心机、细胞破碎仪、水浴箱、振荡器、OLYMPUSAU400全自动生化分析仪、722分光光度计、游泳箱、铅皮、计时器、血色素吸管、加样器、试管等。
试验方法:通过负重游泳试验、血清尿素测定、肝糖原测定、血乳酸测定实验来进行功能评定。
试验结果:
经口给与小鼠0.175g/kg·bw、0.35g/kg·bw、1.05g/kg·bw剂量的实施例4的胶囊30天,0.35g/kg·bw、1.05g/kg·bw剂量能延长小鼠的负重游泳时间,1.05g/kg·bw剂量能将抵消数运动后血清尿素水平、降低小鼠的血乳酸曲线下面积,P<0.05。对小鼠肝糖原储备量未见明显影响(P>0.05)。在本实验条件下,提示该样品具有缓解体力疲劳的功能。
具体试验结果数据见下表:
表7实施例4的胶囊对小鼠负重游泳时间的影响
由表7可知,经口给予小鼠不同剂量的实施例4的胶囊30天,中、高剂量组小鼠负重游泳时间明显高于对照组,差异有显著性(P<0.05)。
表8实施例4的胶囊对小鼠血清尿素的影响
由表8可知,经口给予小鼠不同剂量的实施例4的胶囊30天,高剂量组小鼠血清尿素氮明显低于对照组,差异有显著性(P<0.05)。
表9实施例4的胶囊对小鼠血乳酸变化的影响
由表9可知,经口给予小鼠不同剂量的实施例4的胶囊30天,高剂量组小鼠血乳酸曲线下面积明显低于对照组,差异有显著性(P<0.05)。
Claims (9)
1.一种缓解疲劳的药物,其特征在于,是黑木耳母种以中药原料药混合物的中药水提取液为培养基的发酵产物;所述中药原料药混合物的重量份组份为:玛咖15~45份、枸杞子10~35份、西洋参5~15份、石斛25~35份、银耳15~35份、菊花10~30份。
2.根据权利要求1所述的药物,其特征在于,所述中药原料药混合物的重量份组份为:玛咖25、枸杞子20份、西洋参10份、石斛30份、银耳25份、菊花20份。
3.根据权利要求1或2所述的药物,所述黑木耳母种指黑木耳试管母种,接种量为每100kg所述中药水提取液中接种5~15管18mm×180mm规格的所述试管母种。
4.根据权利要求1或2所述的药物,其特征在于,所述黑木耳母种指黑木耳菌丝母种液,接种量为:黑木耳菌丝母种液与中药水提取液的体积比例为5~15:100。
5.根据权利要求4所述的药物,其特征在于,所述黑木耳菌丝母种液是由黑木耳试管母种以含有辅料的中药水提取液作为液体培养基制备而得,所述辅料的重量份组份为:磷酸氢二钾8份、磷酸二氢钾7份、硫酸锌2份、鹿胎粉10份、白糖40份、酵母浸膏20份、营养琼脂培养基100份,所述辅料占液体培养基的6~10%(w/w)。
6.以权利要求1~5任一所述的药物为有效成分的药剂。
7.权利要求1~5任一所述的缓解疲劳的药物的制备方法,其特征在于:将黑木耳母种接种到所述中药水提取液中发酵。
8.根据权利要求7所述的方法,其特征在于,所述发酵的步骤为:
(1)制备中药水提取液:向所述中药原料药的混合物中加饮用水煎煮提取4~5次,每次过滤取药汁,最后一次弃渣,合并所取的药汁得中药水提取液,所述中药水提取液的总质量是原料药总重量的5~10倍;
(2)接种:对所述中药水提取液进行常压灭活,待冷却至常温,接种黑木耳菌丝母种;
(3)深层发酵:发酵时间为72~144小时。
9.根据权利要求8所述的方法,其特征在于,所述常压灭活指常压下水蒸汽灭活12小时,所述深层发酵72~144小时后,还需对发酵产物进行放罐、浓缩、焙干、过筛最后得粉状制品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710280800.7A CN106924548A (zh) | 2017-04-26 | 2017-04-26 | 一种缓解疲劳的药物及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710280800.7A CN106924548A (zh) | 2017-04-26 | 2017-04-26 | 一种缓解疲劳的药物及制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106924548A true CN106924548A (zh) | 2017-07-07 |
Family
ID=59436845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710280800.7A Pending CN106924548A (zh) | 2017-04-26 | 2017-04-26 | 一种缓解疲劳的药物及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106924548A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107693752A (zh) * | 2017-11-22 | 2018-02-16 | 中山市择朋生物科技有限公司 | 一种用于银屑病的口服制品与制备方法 |
CN107714765A (zh) * | 2017-11-22 | 2018-02-23 | 中山市择朋生物科技有限公司 | 一种用于荨麻疹的口含服制品及其制备方法 |
CN108379544A (zh) * | 2018-05-24 | 2018-08-10 | 魏秀宇 | 一种治疗痤疮的药物及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102613555A (zh) * | 2012-03-30 | 2012-08-01 | 石药集团中奇制药技术(石家庄)有限公司 | 一种玛咖粉人参组合物及其制备方法 |
CN103405657A (zh) * | 2013-06-27 | 2013-11-27 | 广东三才石岐制药有限公司 | 一种治疗咳嗽的药物及其制备方法 |
-
2017
- 2017-04-26 CN CN201710280800.7A patent/CN106924548A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102613555A (zh) * | 2012-03-30 | 2012-08-01 | 石药集团中奇制药技术(石家庄)有限公司 | 一种玛咖粉人参组合物及其制备方法 |
CN103405657A (zh) * | 2013-06-27 | 2013-11-27 | 广东三才石岐制药有限公司 | 一种治疗咳嗽的药物及其制备方法 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107693752A (zh) * | 2017-11-22 | 2018-02-16 | 中山市择朋生物科技有限公司 | 一种用于银屑病的口服制品与制备方法 |
CN107714765A (zh) * | 2017-11-22 | 2018-02-23 | 中山市择朋生物科技有限公司 | 一种用于荨麻疹的口含服制品及其制备方法 |
CN108379544A (zh) * | 2018-05-24 | 2018-08-10 | 魏秀宇 | 一种治疗痤疮的药物及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101760478B (zh) | 一种葛根红曲的制造方法 | |
CN104232441A (zh) | 一种健康保健养生虫草酒及其制备方法 | |
CN106072578A (zh) | 具有增强人体免疫功能的酵素组合物、泡腾片及制法 | |
CN106174485A (zh) | 具有强肾壮阳功效的酵素组合物、泡腾片及制备方法 | |
CN102965235B (zh) | 一种板栗养生酒 | |
CN106721803A (zh) | 一种富硒海蓬子保健饮料 | |
CN106244372A (zh) | 一种改善睡眠的酵素化天麻养生饮品及制备工艺及应用 | |
CN106360213A (zh) | 一种黄精植物饮料及其制备方法 | |
CN109528814A (zh) | 一种乳酸菌发酵黄芪的微生态制剂及其制备方法和应用 | |
CN107279984A (zh) | 具有增强免疫力和缓解体力疲劳功能性健康产品的制备技术 | |
CN104352552A (zh) | 一种食品、保健品或药物组合物 | |
CN104543822A (zh) | 一种发酵中药解酒功能饮品的制备方法 | |
CN106924548A (zh) | 一种缓解疲劳的药物及制备方法 | |
CN103405657B (zh) | 一种治疗咳嗽的药物及其制备方法 | |
CN110710678A (zh) | 一种滋补肝肾、养血安神海洋多肽阿胶膏及其制备方法 | |
CN106235318A (zh) | 以金银花、姜黄为主要原料制备酵素的方法 | |
CN111700142B (zh) | 一种发酵茯苓酸代用茶的制备方法 | |
CN102670669A (zh) | 抗癌抗病毒抗疲劳益肾富硒冬虫夏草菌粉及胶囊 | |
CN108066384A (zh) | 一种具有增强免疫力功能的中药制剂及其制备方法 | |
CN102028718A (zh) | 一种解酒毒的药物及其制备方法 | |
CN105727253A (zh) | 保肝清毒预防治疗肝脏及相关代谢性疾病的组合物及制备方法 | |
CN107898920A (zh) | 一种用于糖尿病的口含制品与制备方法 | |
CN107997153A (zh) | 一种黄精复合保健食品及其制备方法 | |
CN107223966A (zh) | 一种用于提高免疫力的蓉草甘口服液及其制备方法 | |
CN106036307A (zh) | 蛹虫草多糖复方饮液及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170707 |